Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry-Reference-Cited by-同舟云学术

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Published:2021-10-18 Issue:3 Volume:1 Page:
ISSN:2752-4191
Container-title:European Heart Journal Open
language:en
Short-container-title:

Author:

Selvarajah Abi¹^ORCID,Tavenier Annerieke H¹,Bor Wilbert L²,Houben Vital³,Rasoul Saman³⁴,Kaplan Eliza⁵,Teeuwen Koen⁶,Hofma Sjoerd H⁷,Lipsic Erik⁸,Amoroso Giovanni⁹,van Leeuwen Maarten A H¹,ten Berg Jur M²¹⁰,van ‘t Hof Arnoud W J¹³⁴¹⁰,Hermanides Renicus S¹

Affiliation:

1. Department of Cardiology, Isala Hospital, Zwolle, The Netherlands

2. Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands

3. Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands

4. Department of Cardiology, MUMC+, Maastricht, the Netherlands

5. Department of Cardiology, Venlo VieCuri Medical Center, Venlo, The Netherlands

6. Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands

7. Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands

8. Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

9. Department of Cardiology, OLVG Hospital, Amsterdam, The Netherlands

10. Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands

Funder

Grupo Ferrer Internacional

Publisher

Oxford University Press (OUP)

Link

http://academic.oup.com/ehjopen/advance-article-pdf/doi/10.1093/ehjopen/oeab028/40722419/oeab028.pdf

Reference4 articles.

1. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS);Valgimigli;Eur Heart,2017

2. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction;Alexopoulos;Circ Cardiovasc Interv,2012

3. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data;Steg;Lancet,2013

4. Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry;Selvarajah;BMC Cardiovasc Disord,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet strategy during ad-hoc percutaneous coronary intervention in elective patients: how aggressive should we be?;Netherlands Heart Journal;2023-10-20

2. Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome;Journal of Clinical Medicine;2022-09-23